20 completed, 3 unknown, 2 terminated. 25 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 25 | Completed 20, Unknown 3, Terminated 2 |
Follow Acromegaly: new trials by email Literature Review of Acromegaly trials Research Report on Acromegaly
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pasireotide LAR and Pegvisomant Study in Acromegaly Pasireotide LAR 60 mg, Pegvisomant - Acromegaly | Phase 4 | Unknown | Erasmus Medical Center | 60 | 2015-08-01 | 2016-08-03 |
| Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly Pasireotide s.c., Sitagliptin, Liraglutide - Cushing's Disease, Acromegaly | Phase 4 | Completed | Novartis Pharmaceuticals | 249 | 2014-05-23 | 2019-05-29 |
| Hormonal Outcomes in Acromegalic Patients With Treated Surgery With or Without Long Acting Somatostatin Analogues Sandostatin (Octreotide Acetate) - Acromegaly | Phase 4 | Unknown | Asan Medical Center | 1 | 2014-03-01 | 2015-04-28 |
| Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies Pasireotide, Cabergoline, Pasireotide LAR - Cushing's Disease, Acromegaly | Phase 4 | Completed | RECORDATI GROUP | 337 | 2013-06-10 | 2024-10-01 |
| A Pilot Study of Pre- and Post-operative Use of Somatuline Depot. lanreotide - Acromegaly | Phase 4 | Terminated | Saint John's Cancer Institute | 4 | 2013-05-01 | 2021-09-30 |
| Treatment of Acromegaly With Somatostatin Analogs: GH vs. IGF-I as Primary Biochemical Target Sandostatin® LAR - Acromegaly | Phase 4 | Completed | University of Aarhus | 84 | 2012-06-01 | 2017-01-26 |
| Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic Subjects Lanreotide Autogel 120 mg - Acromegaly | Phase 4 | Completed | Ipsen | 124 | 2008-10-01 | 2019-01-29 |
| Acute Application of Pegvisomant and Octreotide in Acromegaly pegvisomant, combination with somatostatin analogue octreotide, combination with dopamine agonist cabergoline - Acromegaly | Phase 4 | Completed | Ludwig-Maximilians - University of Munich | 10 | 2008-01-01 | 2008-04-01 |
| Ultrasound Guided Octreotide LAR Injection in Acromegaly Octreotide LAR 30 MG Injection - Acromegaly | Phase 4 | Completed | Cedars-Sinai Medical Center | 15 | 2007-07-01 | 2018-09-11 |
| Change in Quality of Life After Addition of Weekly 40 mg Pegvisomant/Placebo in Controlled Acromegalic Patients Pegvisomant - Quality of Life, Acromegaly | Phase 4 | Completed | Erasmus Medical Center | 20 | 2006-10-01 | 2008-03-25 |
| Effects of Sandostatin LAR® in Acromegaly Sandostatin LAR - Acromegaly | Phase 4 | Completed | Columbia University | 21 | 2006-10-01 | 2024-07-24 |
| Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients Sandostatin LAR, pegvisomant, cabergoline - Acromegaly | Phase 4 | Completed | Novartis Pharmaceuticals | 70 | 2006-09-01 | 2017-03-03 |
| Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant pegvisomant - Acromegaly, Heart Failure | Phase 4 | Unknown | University of Wuerzburg | 4 | 2006-06-01 | 2010-09-24 |
| Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly Octreotide acetate and cabergoline/Octrotide and Somavert - Acromegaly | Phase 4 | Completed | Novartis Pharmaceuticals | 20 | 2006-03-01 | 2017-03-06 |
| Canadian Pegvisomant Compassionate Study In Acromegalic Patients Pegvisomant treatment, Medical History, demographics, Sign and symptoms: questionnaire - Acromegaly | Phase 4 | Completed | Pfizer | 30 | 2004-11-01 | 2008-04-24 |
| Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR Lanreotide (Autogel formulation) - Acromegaly | Phase 4 | Completed | Ipsen | 8 | 2004-06-01 | 2019-08-16 |
| Somatuline Autogel: Acromegaly Self/Partner Injection Study Lanreotide (Autogel formulation) - Acromegaly | Phase 4 | Completed | Ipsen | 30 | 2004-02-01 | 2019-08-05 |
| Pegvisomant And Sandostatin LAR Combination Study Pegvisomant/ Sandostatin LAR, Sandostatin LAR, Pegvisomant - Acromegaly | Phase 4 | Completed | Pfizer | 75 | 2003-10-01 | 2008-04-07 |
| A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With Acromegaly Pegvisomant, Sandostatin LAR - Acromegaly | Phase 4 | Completed | Pfizer | 100 | 2003-04-01 | 2008-04-07 |
| Study Assessing the Efficacy and Safety of Octreotide Acetate in Patients With Acromegaly, With Micro or Macroadenomas Octreotide acetate - Acromegaly | Phase 4 | Terminated | Novartis Pharmaceuticals | 50 | 2003-03-01 | 2012-04-26 |
Showing 20 of 25. Sign in to see all of them.
Pituitary Neoplasms (4) · Neoplasms (2) · Pituitary ACTH Hypersecretion (2) · Brain Neoplasms (1) · Cardiomegaly (1) · Dumping Syndrome (1) · Gigantism (1) · Heart Failure (1) · Hyperglycemia (1) · Hypertrophy (1) · Hypertrophy, Left Ventricular (1) · Melanoma (1) · Neuroendocrine Tumors (1) · Prostatic Neoplasms (1)
Bone Diseases (25) · Bone Diseases, Endocrine (25) · Brain Diseases (25) · Central Nervous System Diseases (25) · Endocrine System Diseases (25) · Hyperpituitarism (25) · Hypothalamic Diseases (25) · Musculoskeletal Diseases (25) · Nervous System Diseases (25) · Pituitary Diseases (25) · Central Nervous System Neoplasms (4) · Endocrine Gland Neoplasms (4) · Hypothalamic Neoplasms (4) · Neoplasms by Site (4) · Nervous System Neoplasms (4)
pegvisomant (8) · Octreotide (6) · lanreotide (4) · Cabergoline (3) · pasireotide (3) · Demography (1) · Glucose Tolerance Test (1) · Health Records, Personal (1) · Injections (1) · Insulin (1) · Liraglutide (1) · Metformin (1) · Sitagliptin Phosphate (1)
Novartis Pharmaceuticals (5) · Ipsen (3) · Pfizer (3) · Erasmus Medical Center (2) · Federico II University (2) · Asan Medical Center (1) · Cedars-Sinai Medical Center (1) · Columbia University (1) · Ludwig-Maximilians - University of Munich (1) · Odense University Hospital (1) · RECORDATI GROUP (1) · Saint John's Cancer Institute (1) · St. Olavs Hospital (1) · University of Aarhus (1) · University of Wuerzburg (1)
Germany (7) · United States (7) · Italy (6) · Brazil (5) · France (5) · Canada (4) · Denmark (4) · Netherlands (4) · Norway (4) · Poland (4) · Spain (4) · Australia (3) · Greece (3) · Mexico (3) · Russia (3)
Annamaria AL Colao, Prof. (1) · Annamaria Colao, MD, PhD (1) · Bruno Allolio, MD (1) · Daniel F Kelly, MD (1) · Jochen Schopohl, MD (1) · John Carmichael, MD (1) · Marianne Andersen, MD, PhD (1) · Pamela U Freda, MD (1) · Sebastian Neggers, MD PhD (1)
PMID 15613435, PMID 15827109, PMID 10469005, PMID 10690849, PMID 10999798, PMID 11397887, PMID 11788630, PMID 12843148, PMID 14764779, PMID 15070920, PMID 15080776, PMID 15080778, PMID 15099442, PMID 15362960, PMID 15886238, PMID 15886256, PMID 16373932, PMID 16449332, PMID 16487447, PMID 16537687, PMID 16918950, PMID 17259801, PMID 17555511, PMID 17892497, PMID 17984237, PMID 18492760, PMID 19094074, PMID 20003832, PMID 21521254, PMID 24092547, PMID 24866574, PMID 27405306, PMID 29155991, PMID 34275099, PMID 3899825, PMID 5427331, PMID 8050136, PMID 8327647, PMID 8514973, PMID 9709939, PMID 9768640, PMID 9768641, PMID 9808008
2005 (1), 2014 (1)